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Abstract
Introduction High morbidity and mortality rates in patients with
severe acute pancreatitis are mainly caused by bacterial
superinfection of pancreatic necrosis and subsequent sepsis.
The benefit of early prophylactic antibiotics remains
controversial because clinical studies performed to date were
statistically underpowered. Thus, the aim of this study was to
evaluate on-demand versus prophylactic antibiotic treatment in
a standardised experimental model.
Methods Treatment groups received meropenem either
therapeutically 24 hours after induction of necrotising
pancreatitis or prophylactically before development of
pancreatic superinfection. At 24 and 72 hours, pancreatic injury
was investigated by histology and translocation by bacterial
cultures of pancreatic tissue and mesenteric lymph nodes.
Septic complications were evaluated by blood cultures and
survival.
Results Without antibiotic treatment, pancreatic superinfection
was observed in almost all cases after induction of necrotising
pancreatitis. The 72-hour-mortality rate was 42.9% and
bacterial infection of mesenteric lymph nodes and bacteraemia
was found in 87.5% of the surviving animals. Therapeutic
administration of meropenem on-demand reduced bacteraemia
to 50% and mortality to 27.3%. However, prophylactic antibiotic
treatment significantly reduced bacteraemia to 25.0% (p =
0.04) and pancreatic superinfection as well as mortality to 0%
(p < 0.001 and p = 0.05, respectively) compared with controls.
Conclusions In the present study both prophylactic and
delayed antibiotic treatment on-demand reduced septic
complications in a standardised setting of experimental
necrotising pancreatitis. However, pancreatic superinfection,
bacteraemia and mortality rates were reduced significantly by
early treatment. Thus, in the absence of statistically relevant and
well-designed clinical trials, the study demonstrates that
prophylactic antibiotic treatment is superior to antibiotic
treatment on-demand.
Introduction
Although, the clinical course of acute pancreatitis is often mild
and self-limiting, in 15% to 20% of patients severe necrotising
pancreatitis develops, associated with local or systemic com-
plications and high mortality rates [1]. One of the main reasons
for fatal aggravation of the disease is bacterial superinfection
of necrotic pancreatic tissue and the subsequent development
of septic complications [2-4]. The risk of pancreatic superin-
fection is dependent on the amount of necrosis. The risk is
about 20% if necrosis is less than 50% and increases up to
70% when pancreatic necrosis exceeds 50% [5].
In order to evaluate the benefit of prophylactic antibiotic appli-
cation, a number of randomised controlled clinical trials have
been published over the past 15 years [6-14]. Since the
results were conflicting and most studies were of low method-
ological quality and/or statistically underpowered, meta-analy-
ses have been performed to assess this important issue [3,15-
17]. However, the results of several recent meta-analyses
were also controversial. Some reported a benefit of prophylac-
tic antibiotic treatment to avoid pancreatic superinfection [15-
17], some did not find significant differences [18,19]. Others
found that antibiotic prophylaxis was associated with
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decreased mortality but not with a decrease of extrapancreatic
infections, infected pancreatic necrosis or operative treatment
rates [3]. Due to these previously conflicting results, the
Cochrane review in 2006 concluded that more trials were
needed to confirm the benefits of antibiotic prophylaxis [3].
Consequently, until today there remain diverse treatment rec-
ommendations. Although most national and international
guidelines for the management of acute pancreatitis recom-
mend the use of early prophylactic broad-spectrum antibiotics
[20,21], others do not [22,23].
There are a number of reasons why clinical trials and meta-
analyses concerning the benefit of antibiotic prophylaxis in
acute pancreatitis remain controversial. First, the severity of
acute pancreatitis of patients included in studies showed
great variations. For example, due to a lack of patient recruit-
ment, several clinical trials included patients with an overall
rate of pancreatic infected necrosis of 20% or less [6,7,9,10],
which is lower than the expected 40% to 70% in the natural
course of this disease as described by Beger and colleagues
[24]. Furthermore, there was a great heterogeneity in manage-
ment of acute pancreatitis. In some studies [14] patients were
included up to 120 hours after onset of symptoms, at points in
time when pancreatic necrosis was completely developed and
in some cases already superinfected [24].
The most significant change in the clinical course of acute
pancreatitis over the past decades has been the decrease in
mortality from 40% to about 20%, mainly due to improvement
of intensive care management. This decrease of mortality not
only makes it difficult to compare recent studies to trials per-
formed several years ago, it also has to be taken into account
for calculations of trial sample size when considering mortality
as an end-point. Also, many patients in recent studies showed
relatively mild necrotising pancreatitis with less than 30%
necrosis. Therefore, power calculations should be based on a
pancreatic superinfection rate of about 20% compared with
historical data, in which the rate of pancreatic necrosis was
50%. Theoretically, in order to prove that a reduction in
infected necrosis decreases mortality from 20% to 10%, more
than 3000 patients would have to be included in a clinical
study [25]. In contrast to this, almost all trials performed in the
past recruited only a small number of patients and even in the
most recent published study, which was performed in 32 cen-
tres, the calculated number of patients (n = 240) was not
reached and the study terminated early [14]. Therefore, all
studies performed so far were statistically underpowered and
it becomes clear that given the heterogeneity in patient man-
agement, it is difficult, or near impossible, to achieve the
required number of patients in the future.
Due to variations in methodological quality, treatment regi-
mens and the difficulty of including enough patients for a pow-
erful study, the question of efficiency of antibiotic prophylaxis
in acute necrotising pancreatitis can not be answered by clin-
ical studies. In contrast to most medical treatments, where
results from animal experiments are validated by clinical stud-
ies, in this case it was necessary to revert to animal experi-
ments to create standardised settings in order to compare
different antibiotic regimens. Thus, the aim of the present
study was to evaluate the effects of antibiotic treatment in
acute necrotising pancreatitis in a standardised animal model,
and to investigate if there is a difference between the effi-
ciency of early prophylactic antibiotic treatment and on-
demand therapy after occurrence of proven infected necrosis.
Materials and methods
Experimental animals
Inbred male Wistar rats weighing 300 to 340 g (n = 68) were
used for the experiments. Care was provided in accordance
with the German law for use of laboratory animals (BGB1.I S.
1319). The study was approved by the Committee of Animal
Care of the Regierungspräsidium Karlsruhe, Germany. Ani-
mals were allowed free access to food and water before start-
ing the experiments.
Anaesthesia and catheter placement
Surgical anaesthesia was induced by a short carbon dioxide
narcosis followed by 40 mg/kg intramuscular ketamine (Ket-
anest® S 25 mg/ml, Parke-Davis, Berlin, Germany) and 6 mg/
kg xylazin (20 mg/ml Rompun® 2%, Bayer AG, Leverkusen,
Germany). The left internal jugular vein was cannulated using
a soft polyethylene catheter (0.5 mm ID, 0.8 mm OD, Braun
Melsungen, Germany) for infusion regimens. The catheter was
tunnelled subcutaneously to the suprascapular area and
brought out through a steel tether that allowed free movement
of the animals.
Induction of acute necrotising pancreatitis
A detailed description of the induction technique has been
reported previously [26]. In brief, the common bile duct was
punctured and glycodeoxycholic acid (GDOC, Sigma-Aldrich
Inc., St. Louis, USA) in glycyl-glycine-NaOH buffered solution
(pH 8.0, room temperature) at a concentration of 10 mmol/L
was infused in a time- (10 minute), pressure- (30 mmHg) and
volume-controlled fashion (1.2 ml/kg). Subsequently, animals
received a continuous intravenous infusion of 5 μg/kg/hour (6
ml/kg/hour) caerulein (Caerulein, Sigma-Aldrich Inc., St. Louis,
USA) over six hours followed by volume substitution with 6 ml/
kg/hour sodium chloride (NaCl) solution.
Experimental design
In our first set of experiments, all animals were euthanased at
24 hours after induction of acute necrotising pancreatitis. At
the end of the 24-hour period, pancreatic injury was evaluated
by histological assessment of oedema, inflammation and
necrosis. Animals (n = 6) receiving prophylactic antibiotic
treatment (40 mg/kg intravenous Meropenem®, AstraZeneca
GmbH, Wedel, Germany) every eight hours as a single dose
started six hours after induction of acute pancreatitis) wereAvailable online http://ccforum.com/content/12/6/R141
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compared with a control group (n = 6) that did not receive anti-
biotic treatment (Figure 1). Septic complications were evalu-
ated by bacteriological assessments of blood, ascites,
pancreas and mesenteric lymph nodes of both the colon and
small bowel, as well as by 24-hour mortality rates.
In a second set of experiments, treatment effects of mero-
penem were evaluated 72 hours after induction of necrotising
pancreatitis. Only animals that survived the first 24 hours after
induction of acute pancreatic were included in the analysis.
The results of our first experimental group demonstrated that
superinfection of pancreatic necrosis is present in all animals
at 24 hours. In order to imitate the clinical setting of severe
necrotising pancreatitis, animals were treated with mero-
penem either prophylactically before infection of pancreatic
necrosis was observed, or therapeutically after superinfection
of pancreatic necrosis was present (Figure 1).
Thus, the first group of animals (n = 8) was infused with mero-
penem therapeutically after a therapy-free interval of 24 hours,
which corresponds to treatment on-demand in the clinical set-
ting. The second group (n = 8) received meropenem at six
hours after induction of acute pancreatitis. At this point, pan-
creatic necrosis had already been established [26], but
necrotic tissue was not yet superinfected because bacterial
translocation occurs about 18 hours after induction of acute
pancreatitis in severe experimental pancreatitis [27]. In the
clinical setting this corresponds to a patient who presents to
the hospital within the first three days after onset of the dis-
ease and receives antibiotics prophylactically. After induction
of acute pancreatitis, animals received a continuous standard-
ised intravenous volume substitution with 6 ml/kg/hour NaCl
solution. A third group served as controls and received the
same fluid regimen using NaCl instead of meropenem.
To evaluate bacterial and fungal infection in the long-term
postoperative course, we investigated animals from the pro-
phylactic antibiotic treatment group after seven days (n = 6).
The focus of investigations in this experimental group was to
evaluate the rate of fungal infection after prophylactic antibi-
otic treatment. Six animals underwent sham laparotomy with-
out induction of acute pancreatitis and served as controls.
Animals received intraductal saline and intravenous saline
only. All parameters as described above were evaluated.
All animals were fasted for the first 24 hours of the experiment
and received 6 ml/kg/hour NaCl as volume therapy. After 24
hours, animals had free access to food and water. Animals that
died of technical or anaesthesiological complications were
excluded from the study. In the second set of experiments, only
animals that survived more than 24 hours after induction of
acute pancreatitis were included.
Bacteriology and mycology
A relaparotomy was performed 24 hours or 72 hours after
induction of acute pancreatitis. First, ascites was collected
and blood was drawn directly by cardial puncture after open-
ing the thorax. Tissue of the pancreas, and the mesenteric
lymph nodes of the colon and small bowel were collected
under sterile conditions. Bacterial and fungal growth derived
from minced tissue samples was evaluated after 72 hours of
enrichment on standardised media at 37°C.
Figure 1
Experimental design Experimental design. Animals in all treatment groups received induction of acute necrotising pancreatitis at time point 0. In experimental group 1, 
animals were euthanased at 24 hours. Prophylactic antibiotic treatment (starting six hours after induction of pancreatitis) was evaluated versus no 
antibiotic treatment. In a second experimental group, animal were euthanased at 72 hours. Meropenem therapy on-demand (starting at 24 hours 
after induction of pancreatitis) was compared with prophylactic treatment and controls.Critical Care    Vol 12 No 6    Fritz et al.
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Laboratory
Blood was drawn by intracardial puncture for measurement of
amylase, lipase, and white and red blood cell count from arte-
rial blood.
Histological assessment
Histomorphological evaluation of the pancreas was performed
by an investigator who was unaware of the experimental
design using a scoring system previously described in detail
[26]. In brief, the head of the pancreas was removed, fixed in
4% buffered formalin and embedded in paraffin. Coronal sec-
tions were made in the plane of the flattened pancreas and
stained with H&E. Morphometric documentation included
evaluation of oedema, inflammation and acinar necrosis using
a scoring system from 0 (no injury) to 3 (severe injury) [26].
Data analysis and statistics
Data is presented as mean ± standard error of the mean
(SEM). Data was analysed using the SPSS Software (Version
11.5.1 for Windows, LEAD Technologies Inc., Greenwood
Cliff, USA). Differences between groups were compared
using analysis of variance and by the student's t-test and
fisher's exact test. Statistical significance was accepted at the
5% level (p ≤ 0.05).
Results
Control versus prophylactic meropenem therapy 
(animals euthanased 24 hours after induction of acute 
pancreatitis)
Bacteriology and mycology
Severe bacterial infection was found in blood, ascites and pan-
creatic tissue of almost all animals at 24 hours after induction
of acute pancreatitis (Figure 2). Germs were composed of
mainly Gram-negative enteral bacteria including Pseu-
domonas and Enterococcus. Furthermore, bacterial specifica-
tion showed typical enteral flora in mesenteric lymph nodes of
the small bowel and colon. There were no significant differ-
ences between the germs in the small bowel and colonic
lymph nodes.
In contrast, in the prophylactic antibiotic treatment group only
one out of six rats showed bacterial infection of blood, pancre-
atic necrosis and lymph nodes of the small bowel. Although
two animals displayed bacterial infection of ascites,
mesenteric lymph nodes of the colon did not show any signif-
icant translocation (Figure 2). In addition, no fungal infection
was observed at 24 hours after induction of necrotising pan-
creatitis.
The sham-operated animals without acute pancreatitis had no
bacterial superinfection, neither in the pancreas nor in other
examined tissues (Figure 2).
Mortality
All sham-operated control animals survived, while induction of
severe necrotising pancreatitis was associated with a 24-hour
mortality rate of 57.1%. In contrast, prophylactic administra-
tion of meropenem reduced mortality of acute pancreatitis sig-
nificantly to 0% (p = 0.007; Figure 3). Thus, all animals that
received meropenem prophylactically survived 24 hours after
induction of acute necrotising pancreatitis.
Laboratory
In arterial blood, red and white blood cell count, amylase and
lipase levels were significantly higher in the pancreatitis group
compared with controls without induction of pancreatitis.
Figure 2
Bacterial superinfection at 24 hours Bacterial superinfection at 24 hours. Meropenem given prophylactically reduced bacterial infection of blood, ascites, pancreas, and lymph nodes 
of the small bowel (LN Sm.bo.) and colon (LN Colon) 24 hours after induction of acute pancreatitis (*p = 0.015).Available online http://ccforum.com/content/12/6/R141
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However, amylase and lipase levels did not differ between
early prophylactic antibiotic treatment and no treatment (data
not shown).
Histology
Histology showed severe acute necrotising pancreatitis in all
animals except shams 24 hours after induction of acute pan-
creatitis (Table 1). There were no significant differences
between early prophylactic antibiotic treatment versus no
treatment.
Prophylactic versus on-demand therapy (animals 
euthanased 72 hours after induction of acute 
pancreatitis)
Bacteriology and mycology
In controls without antibiotic treatment, severe bacterial infec-
tion of blood, ascites and mesenteric lymph nodes was found
at 72 hours after induction of necrotising pancreatitis in seven
out of eight cases (Figure 4). In all of these animals we found
superinfection of the pancreas with enteral bacterial flora such
as Escherichia coli, Pseudomonas or Enterococcus. Both pro-
phylactic and therapeutic antibiotic treatment reduced bacte-
rial infection of blood, pancreatic tissue and mesenteric lymph
nodes of the small bowel and colon (Figure 4). Compared with
the control group, prophylactic treatment significantly reduced
bacterial infection of blood (p = 0.041), pancreatic tissue (p <
0.001) and mesenteric lymph nodes of the small bowel (p =
0.010) and colon (p = 0.001). In contrast, therapeutic antibi-
otic treatment on-demand only reduced pancreatic superin-
fection and infection of mesenteric lymph nodes of the colon
compared with controls (p = 0.026 and p = 0.039). Further-
more, the decrease of bacterial infection was less pronounced
compared with prophylactic antibiotic treatment. Again, no
fungal infection was evident in examined tissues.
Mortality
Without antibiotic treatment a 72-hour mortality rate of 42.9%
(6 of 14 animals) was observed in severe necrotising pancre-
atitis. Animals died of cardiorespiratory decompensation
through the whole observation period. The time-points of
Figure 3
Survival rates at 24 and 72 hours Survival rates at 24 and 72 hours. *p = 0.01 and #p = 0.05 compared with controls.
Table 1
Histological parameters at 24 hours
Feature Pancreatitis (no therapy)
Mean (range)
(n = 6)
Prophylactic therapy
Mean (range)
(n = 6)
Control (sham operated)
Mean (range)
(n = 6)
Oedema 2.08 (2 to 2.5) 2.08 (2 to 2.5) 0.08 (0 to 0.5)
Inflammation 2.42 (2 to 3) 2.17 (1.5 to 2.5) 0
Necrosis 2.42 (2 to 3) 2.00 (1.5 to 2.5) 0
Histological score 0 (no injury) to 3 (severe injury) [26]Critical Care    Vol 12 No 6    Fritz et al.
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death were evenly distributed without a peak. Antibiotic treat-
ment administrated therapeutically on-demand reduced mor-
tality to 27.3% (3 of 11 animals), while all animals (n = 8) after
prophylactic antibiotic treatment survived (Figure 3). Thus,
prophylactic antibiotic treatment further decreased mortality
compared with therapeutic administration of meropenem.
Compared with the control group without antibiotic treatment,
the decrease was statistically significant (p = 0.05).
Laboratory
Red and white blood cell counts, amylase and lipase levels
were not significantly different between the three groups
(acute pancreatitis control, meropenem prophylactically and
meropenem therapeutically).
Histology
Severe necrotising pancreatitis was evident at 72 hours after
induction of acute pancreatitis. After prophylactic meropenem
application, pancreatic oedema was significantly reduced
compared with the control group (p < 0.05). However, there
was no significant difference between the two treatment arms,
therapeutic versus prophylactic meropenem administration
(Table 2).
Long-term results (animals were euthansed seven days 
after induction of acute pancreatitis)
In the long-term postoperative course we focused on bacterial
and fungal infection after administration of prophylactic mero-
penem. We did not find any fungal infection in blood, ascites,
pancreas or mesenteric lymph nodes of the small bowel or
colon. Furthermore, bacterial infection of ascites was only
found in two out of six cases, while all other examined tissues
Figure 4
Bacterial superinfection at 72 hours Bacterial superinfection at 72 hours. Both prophylactic and therapeutic antibiotic treatment reduced bacterial infection of blood, pancreatic tissue, 
mesenteric lymph nodes of small bowel (LN Sm.bo.) and colon (LN Colon). Compared with the control group without antibiotic treatment, prophylac-
tic treatment reduced significantly bacterial infection of blood (p = 0.041), ascites (p = 0.039), pancreatic tissue (p < 0.001), mesenteric lymph 
nodes of small bowel (p = 0.010) and colon (p = 0.001). Compared with this, on-demand antibiotic treatment only reduced pancreatic superinfec-
tion and infection of mesenteric lymph nodes of the colon significantly (p = 0.026 and p = 0.039, respectively).
Table 2
Histological parameters at 72 hours
Feature Pancreatitis (no therapy)
Mean (range)
(n = 8)
On-demand therapy
Mean (range)
(n = 8)
Prophylactic therapy
Mean (range)
(n = 8)
Oedema 1.63 (1.5 to 2) 1.56 (1 to 2) 1.13 (0.5 to 1.5)*
Inflammation 2.56 (2 to 3) 2.63 (2.5 to 3) 2.44 (1.5 to 3)
Necrosis 2.31 (2 to 3) 2.44 (1.5 to 3) 2.31 (1.5 to 3)
Histological score 0 (no injury) to 3 (severe injury) [26]; *p < 0.05 (prophylactic therapy versus pancreatitis)Available online http://ccforum.com/content/12/6/R141
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did not show any bacterial infection. In these experiments, all
animals that received prophylactic antibiotics survived the
whole observation period of seven days.
Discussion
Mortality of acute pancreatitis is about 1% to 5%, but in cases
of superinfection of pancreatic necrosis mortality it increases
dramatically up to 20% to 85% [2,21,24,28,29]. Due to major
improvements in intensive-care management over the past
decade, more patients survive the first phase of severe acute
pancreatitis and therefore the prophylaxis and treatment of
infected necrosis is of increasing clinical importance [30]. In
many cases infected pancreatic necrosis results in the devel-
opment of multiple organ failure or septic complications and is
associated with high mortality rates [2,31,32]. Although vari-
ous studies [8-10,13,33] and meta-analyses [15,16] have
detected a beneficial role of early prophylactic treatment in
acute pancreatitis, two recent double-blind studies [7,14]
could not demonstrate any beneficial effects of antibiotic
prophylaxis with respect to the risk of developing infected pan-
creatic necrosis and mortality. However, the study by Isen-
mann and colleagues [7] included mainly patients with mild to
moderate pancreatitis, as seen by the low rate of superinfec-
tion and low mortality rate even in the control group. Regard-
less, the indication for antibiotic prophylaxis in necrotising
pancreatitis remains controversial [3,7,17,25].
Over the past decade, it has become clear that because of var-
iations in patient recruitment and treatment regimens it is
almost impossible to include enough patients for a meaningful
clinical trial [25]. Consequently, the question whether antibi-
otic prophylaxis in acute necrotising pancreatitis is effective in
clinical practice can not be answered by clinical studies. Thus,
the aim of the present study was to use a well standardised
animal model to investigate the efficiency of early prophylactic
antibiotic treatment compared with on-demand therapy on
pancreatic infection rates, septic complications and mortality.
Although, no experimental model mirrors the clinical setting
completely, duct perfusion models are currently the most pop-
ular models of acute pancreatitis [34], because they are char-
acterised by similar pathophysiological steps as the human
disease [35].
In 1993, Tarpila and colleagues showed that acute pancreati-
tis in a rat model caused systemic bacterial colonisation [28].
They suspected bacterial translocation was the mechanism of
pancreatic infection. In the present study, we found bacterial
infection of blood, ascites and mesenteric lymph nodes of the
colon and small bowel in almost all animals after induction of
severe acute necrotising pancreatitis. The specification
showed typical enteric flora in mesenteric lymph nodes of the
small bowel and colon, which reflects bacterial translocation
from the gut. There was no significant difference between
infection of mesenteric lymph nodes of the colon and small
bowel. The pathogenesis of pancreatic superinfection is not
completely understood [36]. However, our findings are in
agreement with the hypothesis that intra-abdominal spread by
lymphatics is the pathway most likely to be involved in this
process [37].
Despite the fact that in the present study a limited number of
animals were available in each experimental group, we demon-
strated that pancreatic and systemic infection in necrotising
pancreatitis is reduced by prophylactic antibiotic treatment
with meropenem (Figures 2 and 4). Furthermore, it reduced
sepsis-related mortality (Figure 3). Meropenem was used
because it has been shown previously that penetration into
necrotic pancreatic tissue occurred in sufficient therapeutic
concentrations [17,38]. Thus, meropenem might be an effec-
tive antibiotic for prevention of bacterial superinfection of
necrotic pancreatic tissue and its consecutive sepsis. This is
consistent with the clinical findings of many studies on acute
pancreatitis [1,17,21,22] and a recent meta-analysis, which
demonstrated reduced mortality and pancreatic infection rate
with beta-lactam antibiotics compared with others [3].
Recent clinical experience has provided evidence that con-
servative management and early prophylactic antibiotic admin-
istration in sterile necrotising pancreatitis is the treatment of
choice [17,21,25,31]. However, various clinical centres have
diverse strategies for the treatment of acute pancreatitis
[7,18,19]. To date, it remains unclear whether prophylactic
antibiotic treatment or on-demand antibiotic therapy is more
beneficial. Therefore, we also evaluated the effectiveness of
antibiotic on-demand therapy beginning after a latency period
of 24 hours after induction of necrotising pancreatitis versus
early antibiotic prophylaxis (Figure 4).
Both prophylactic and therapeutic treatment on-demand
reduced septic complications and mortality in experimental
necrotising pancreatitis. This is supported by the results of
several clinical trials performed so far [7,14,18,19]. However,
our experiments showed a greater benefit for prophylactic
early antibiotic treatment compared with on-demand therapy
concerning superinfection of the pancreas, mortality and sep-
sis. Already at 24 hours, bacterial infection of lymph nodes of
the colon could be significantly (p = 0.015) reduced from
83.3% to 0% by early antibiotic prophylaxis (Figure 2). These
findings support the hypothesis that translocation of enteric
bacteria occurs during the early stage of acute necrotising
pancreatitis. This is in accordance with the results of rat exper-
iments performed by Foitzik and colleagues [39] and Wang
and colleagues [40], as well as with clinical findings published
by Beger and colleagues [24] and Ammori and colleagues
[41], who found endotoxaemia in 20 of 26 patients with acute
pancreatitis. Therefore, as a result of our experiments we
would recommend to start antibiotic therapy as early as possi-
ble after the diagnosis of pancreatic necrosis has been made.
This is of particular relevance because the latest clinical trialsCritical Care    Vol 12 No 6    Fritz et al.
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were all statistically underpowered and could not show any dif-
ference between these two treatment modalities.
A steady rise in the incidence of pancreatic fungal infections in
severe pancreatitis has been reported [42] and it was hypoth-
esised that the widespread use of antibiotics is the cause for
this phenomenon. There is also some evidence that fungal
infections may worsen the outcome of acute pancreatitis, but
to date this hypothesis has not been proven [43,44]. In fact,
the incidence of fungal infections varies between different tri-
als within a range of 0% to 37% [44]. In our experiments, we
could not detect any fungal infection after induction of necro-
tising pancreatitis at any time point up to seven days. Even the
use of broad-spectrum meropenem with its strong selection
pressure on microorganisms did not result in detectable fungal
infection. In contrast to our experimental standardised setup,
patients in the clinical setting often undergo repeated interven-
tional procedures including central venous lines or urinary
catheters, which might trigger the occurrence of fungal infec-
tions during the course of necrotising pancreatitis [45]. How-
ever, with regard to the present experimental setting, we
cannot exclude that fungal infections might occur at a later
stage.
Conclusion
With regard to the present study and previously published lit-
erature, meropenem is an effective antibiotic drug for the treat-
ment of bacterial pancreatic infection in acute necrotising
pancreatitis [3]. In the experimental model, both prophylactic
and delayed treatment on-demand reduced septic complica-
tions and mortality. Although clinical trials have been statisti-
cally underpowered and consequently could not demonstrate
any difference between antibiotic prophylaxis versus treatment
on-demand, we show that in a standardised model prophylac-
tic administration reduced pancreatic superinfection, mortality
and sepsis more effectively compared with treatment on-
demand. Following our experiments, the administration of anti-
biotics should be started earlier rather than later in the course
of severe pancreatitis associated with pancreatic necrosis.
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